PRUDENT HEALTHCARE - WALES CONFERENCE 2016
In September 2016, AbbVie teamed up with the Bevan Commission to host a conference looking at the progress of the Welsh health system's 'Prudent Healthcare' initiative.
AbbVie is working with partners across the UK healthcare system to try new ideas and spread best practice in healthcare sustainability. Here is what is currently happening with Sustainable Healthcare across the UK.
Click the bullets below for quick navigation through the page:
On 29 November 2016, AbbVie together with the College of Medicine, brought together over 200 health and care professionals, researchers, commissioners and patient representatives, to share and examine how, by ‘going beyond medicine’, we can address the sustainability challenge faced by the NHS.
With AbbVie’s support, charities Addaction and The Hepatitis C Trust set up a pilot initiative in the South West region, designed to widen HCV testing and offer additional support to access appropriate treatment for people who use drugs or who are in recovery.
AbbVie is supporting the creation of the UK’s first Early Intervention Clinic for people who have been signed off work with a MSD. Rolled out by the Leeds Community Healthcare NHS Trust and led by Dr Steve Brennan, the clinic is specifically designed to enable quick referrals from primary care, allowing patients to access a specialist in just five days and reduce the time people with MSDs are signed off from work.
AbbVie is supporting the development of a new shared decision-making (SDM) tool, led by Professor Debbie Cohen at Cardiff University. The SDM tool has been designed to aid and improve conversations and decisions about health and work between patients and their healthcare professionals.
Transition is a make or break period; if managed correctly, it can empower young people to take greater ownership and management of their conditions. If managed incorrectly, or worse, not done at all, the transition period can see adolescents disengage and drop out of contact with the health system altogether, often with severe consequences.
Health and social care systems around the world are attempting to address the challenges of meeting rising health demands of an aging population and the growing number of patients with increasingly complex diseases within the tight financial constraints placed upon public services. Scotland is no different and the pressures are significant...
In 2017, AbbVie is supporting the Greater Manchester Hepatitis C ODN with its ambitious plans to eliminate the disease as a public health concern in the region. An AbbVie grant is piloting a new ‘in-reach’ method of identifying people with hepatitis C who are either undiagnosed or unengaged with the healthcare system.
Work reduces the risk of chronic disability and long-term incapacity. It also reduces poverty and social exclusion and improves a person’s quality of life and wellbeing. However chronic conditions can be disabling and AbbVie is particularly interested in helping people to live well with their conditions.
AbbVie, together with the Bevan Commission and the College of Medicine, brought together representatives from the NHS, local government, third sector and community in September 2016 to share prudent perspectives of four key life stages: older years, working life, teenagers and young people, and the early years.
AbbVie commissioned research in 2016 to gain insights into attitudes of young people towards the role their education has played in helping them to manage their own health. This thought piece examines the findings.
Leave the UK site
The Abbvie Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals and other products or uses of those products that are not approved in other countries or regions. If you are a resident of a country other than those to which the site is directed, please contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.
The Abbvie Internet site that you have requested may be in a language that differs from your country of origin.
The Abbvie Internet site that you have requested may not be optimised for your screen size.
Do you wish to continue to this Abbvie site?
The product-specific Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals and other products or uses of those products that are not approved in other countries or regions. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.
The product-specific Internet site that you have requested may not be optimized for your screen size.
Do you wish to continue to this product-specific site?
The “Yes” link below will take you out of AbbVie family of websites
Links which take you out of AbbVie worldwide web sites are not under the control of AbbVie, and AbbVie are not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.
The Internet site that you have requested may not be optimized to your screen size.
Do you wish to leave this site?